Amlodypine – the ideal antihypertensive agent in the combination theraphy Review article
Article Sidebar
Published:
Mar 31, 2012
Keywords:
amlodipine, combination therapy, hypertension
Main Article Content
Abstract
Hypertension has been recognized as an important risk factor for cardiovascular disease and a leading factor for mortality. In the majority of patients it is necessary to use of more than one agent to achieve target blood pressure. Combination treatment for hypertension as initial therapy can reduce blood pressure to a greater extent and more rapidly. Given the vast array of available antihypertensive agents, the number of potential combinations is large; however, rational choice must be based on the characteristics of each agent and their complementary mechanisms of action. Amlodipine, calcium antagonist, has favourable pharmacokinetic and pharmacodynamics profile, and this agent was widely used with other antihypertensives in clinical trials. Therefore, we presented the main characteristic of amlodipine and preferred drug combination containing amlodipine.
Article Details
How to Cite
Czarnecka, D., & Bednarek, A. (2012). Amlodypine – the ideal antihypertensive agent in the combination theraphy. Medycyna Faktow (J EBM), 5(1(14), 43-48. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2492
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Hipertensjologia. Patogeneza, diagnostyka i leczenie nadciśnienia tętniczego. Wydanie I. Więcek A., Januszewicz A., Szczepańska-Sadowska E., Prejbisz A. (red.). Medycyna Praktyczna, Kraków 2011: 1-22.
2. Leenen F.H., Dumais J., Mcinnis N.H. et al.: Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008; 178(11): 1441-9.
3. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009; 27(11): 2121-58.
4. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15(2): 55-82.
5. Ferrari P., Giachino D., Wiedmann P. et al.: Unaltered insulin sensitivity during calcium channel blockade with amlodipine. Eur. J. Clin. Pharmacol. 1991; 41(2): 109-13.
6. Zanetti-Elsater F., Pingitore R., Beretta-Piccoli C. et al.: Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. Am. J. Hypertens. 1994; 7(1): 36-45.
7. Chanard J., Toupance O., Lavaud S. et al.: Amlodipine reduces cyclosporine-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol. Dial. Transplant. 2003; 18(10): 2147-53.
8. Biblioteka czasopisma Nadciśnienie Tętnicze. Perindopril+amlodipina. Tykarski A. (red.). Via Medica, Gdańsk 2009.
9. Dahlöf B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomizes controlled trial. Lancet 2005; 366: 895-906.
10. Williams B., Lacy P.S., Thom S.M. et al.; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113(9): 1213-25.
11. Jamerson K., Weber M.A., Bakris G.L. et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359(23): 2417-28.
12. Karpov Y., Dongre N., Vigdorchik A. et al.: Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the reallife safety and effectiveness in the routine treatment of hypertension. Adv. Ther. 2012 Jan 20. [online].
13. Boutouyrie P., Achouba A., Trunet P. et al.: Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination. Hypertension 2010; 55: 1314-22.
14. Julius S., Kjeldsen S.E., Weber M. et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363(9426): 2022-31.
15. Wright R., Duprez D., Purkayastha D. et al.: Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the Exforge As Compared to Losartan Treatment in Stage 2 Systolic Hypertension (EXALT) Study. J. Clin. Hypertens. 2011; 13: 588-97.
2. Leenen F.H., Dumais J., Mcinnis N.H. et al.: Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008; 178(11): 1441-9.
3. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009; 27(11): 2121-58.
4. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15(2): 55-82.
5. Ferrari P., Giachino D., Wiedmann P. et al.: Unaltered insulin sensitivity during calcium channel blockade with amlodipine. Eur. J. Clin. Pharmacol. 1991; 41(2): 109-13.
6. Zanetti-Elsater F., Pingitore R., Beretta-Piccoli C. et al.: Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. Am. J. Hypertens. 1994; 7(1): 36-45.
7. Chanard J., Toupance O., Lavaud S. et al.: Amlodipine reduces cyclosporine-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol. Dial. Transplant. 2003; 18(10): 2147-53.
8. Biblioteka czasopisma Nadciśnienie Tętnicze. Perindopril+amlodipina. Tykarski A. (red.). Via Medica, Gdańsk 2009.
9. Dahlöf B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomizes controlled trial. Lancet 2005; 366: 895-906.
10. Williams B., Lacy P.S., Thom S.M. et al.; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113(9): 1213-25.
11. Jamerson K., Weber M.A., Bakris G.L. et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359(23): 2417-28.
12. Karpov Y., Dongre N., Vigdorchik A. et al.: Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the reallife safety and effectiveness in the routine treatment of hypertension. Adv. Ther. 2012 Jan 20. [online].
13. Boutouyrie P., Achouba A., Trunet P. et al.: Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination. Hypertension 2010; 55: 1314-22.
14. Julius S., Kjeldsen S.E., Weber M. et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363(9426): 2022-31.
15. Wright R., Duprez D., Purkayastha D. et al.: Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the Exforge As Compared to Losartan Treatment in Stage 2 Systolic Hypertension (EXALT) Study. J. Clin. Hypertens. 2011; 13: 588-97.